This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why OPKO Health (OPK) Could Be Positioned for a Slump
by Zacks Equity Research
OPKO Health (OPK) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
4 Medical Device Stocks to Top Q3 Earnings
by Zacks Equity Research
A look at how medical device players are poised for this earnings season.
OPKO Health (OPK) Signs New Agreement with Japan Tobacco
by Zacks Equity Research
OPKO Health's (OPK) new agreement with Japan Tobacco will enhance prospects of its kidney drug RAYALDEE in Japan.
Is the Options Market Predicting a Spike in Opko Health (OPK) Stock?
by Zacks Equity Research
Investors in Opko Health (OPK) need to pay close attention to the stock based on moves in the options market lately.
OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2
by Zacks Equity Research
OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More
by Zacks Equity Research
Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.
Is the Options Market Predicting a Spike in Opko Health (OPK) Stock?
by Zacks Equity Research
Surging level of implied volatility makes Opko Health (OPK) Stock lucrative to the option traders.
Medical Product Q1 Earnings on May 8: ITGR, OPK & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 8.
OPKO Health (OPK) Launches Prenatal Testing Tool ClariTest
by Zacks Equity Research
OPKO Health Inc. (OPK) recently announced the launch of a non-invasive medical test to detect fetal abnormalities.
Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation
by Arpita Dutt
Although this was a relatively slow week for the biotech sector, Inotek (ITEK) made it to the headlines on disappointing data on its lead pipeline drug.
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3
by Zacks Equity Research
OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.
4 Medical Device Stocks on a Bull Run this Earnings Season
by Zacks Equity Research
The expected positive third-quarter performance by the broader Medical sector is something investors definitely need to muse on.